Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against ...

The grinding two-plus years of the pandemic have yielded outsize benefits for one company—Pfizer—making it both highly influential and hugely profitable as covid-19 continues to infect tens of ...

On Friday evening, December 18, 2020 the United States Food & Drug Administration (FDA) approved Moderna’s mRNA Covid-19 vaccine for emergency use, joining Pfizer’s previously approved ...

Pfizer posts mixed first-quarter results, maintains annual forecast COVID vaccine sales better-than-expected, while sales of antiviral treatment decline Expects to save $7.7 billion in costs by ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Pfizer also beat analyst expectations for first-quarter earnings as it benefited from cost-saving efforts, although it fell short of Wall Street’s revenue estimate, as sales of its COVID-19 ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

Analysts significantly cut their Paxlovid sales expectations in recent weeks due to a relatively small winter wave of COVID-19 in the U.S. On an adjusted basis, Pfizer earned 92 cents per share in ...

Investors are closely watching for any potential impact on Pfizer's vaccine business and any changes to recommendations for receiving flu, COVID and other shots under the new health secretary Robert F ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and ...

Researchers at Karolinska Institutet have identified biomarkers in the blood associated with symptoms of long COVID, particularly severe respiratory disorders. The discovery can pave the way for ...